RESULT UPDATE

KEY DATA

Rating	BUY
Sector relative	Neutral
Price (INR)	1,989
12 month price target (INR)	2,300
52 Week High/Low	2,195/1,552
Market cap (INR bn/USD bn)	3,179/35.9
Free float (%)	34.2
Avg. daily value traded (INR mn)	2,079.3

SHAREHOLDING PATTERN

(%)	Sep-25	Jun-25	Mar-25
Promoter	58.8	58.8	60.6
FII	8.1	8.4	7.5
DII	10.5	10.1	9.0
Pledge	0.0	0.0	0.0

FINANCIALS (INR mn)				
Year to March	FY25A	FY26E	FY27E	FY28E
Revenue	22,617	26,009	29,911	34,397
EBITDA	20,162	23,273	26,856	30,981
Adjusted profit	15,589	17,705	20,433	23,573
Diluted EPS (INR)	9.7	11.1	12.8	14.7
EPS growth (%)	32.9	14.1	15.4	15.4
RoAE (%)	20.9	19.4	19.0	18.7
P/E (x)	237.1	207.8	180.1	156.1
EV/EBITDA (x)	156.8	135.3	116.7	100.6
Dividend yield (%)	0	0	0	0

PRICE PERFORMANCE



Improving profitability

Insurance subsidiaries of Bajaj Finsery delivered a mixed performance: while BALIC's total APE fell 5.2% YoY, its VNB margin improved 628bp YoY to 17.1% resulting in VNB growth of 49.8% YoY. Elevated expenses (+14.6% YoY) at BAGIC resulted in widened underwriting losses despite a 390bp YoY improvement in loss ratio. PAT improved 4.7% YoY to INR5.2bn driven by investment income (+11.3% YoY).

Given BALIC's margin improvement, we are raising FY27E/28E VNB by 11.1%/11.2%. We are building in CMP of INR950 for Bajaj Finance while valuing BALIC at FY27E P/EV of 1.5x and BAGIC at FY27E P/E of 24x. We roll forward to Sep-27E and consequently, upgrade to 'BUY' from 'HOLD' with a revised TP of INR2,300 (earlier INR2,190).

BAGIC—NEP decreases; loss ratio improves

BAGIC clocked GWP growth of 9.2% YoY to INR64.1bn. GWP was driven by Motor/Property, liability and engineering segments/group health, which surged 18%/18.3%/9.2% YoY. Retail health (9% of GWP) grew 9.2% YoY while growth in government health (13% of GWP) and Agri (15% of GWP) moderated at 1.4%/2.4% YoY. Higher ceding (+22.4% YoY) led to NEP of INR24.1bn (-9.6% YoY). Loss ratios fell to 75.8% (-390bp YoY) as loss ratios for fire, motor TP, and crop improved notably while loss ratio for motor OD segment increased to 70.9% (+590bp YoY). Commission and expense ratio rose 480bp YoY to 26.5%. Management attributed the increase in commission expenses to an increasing share of long-term 2W and 4W policies, which involve upfront commission payments. Overall, combined ratio increased +90bp YoY to 102.3%. For Q2, IRDAI's direction of 1/n accounting for long term products hurt CoR by 90bp i.e., CoR ex-1/n impact was 101.4%. Underwriting loss surged to INR920mn versus INR480mn in Q2FY25. PAT rose to INR5.2bn (+4.7% YoY/-21.7% QoQ) as BAGIC reported investment income of INR7.9bn (+11.3% YoY).

BALIC—Favourable mix aids VNB margin

BALIC's retail/group APE fell 2.4%/19.8% YoY leading to 5.2% fall in Q2FY26 total APE. In Q2, Individual APE product mix shifted in favour of Protection products (share in mix rose 400bp YoY to 8%). This led to VNB margin pickup by 628bp YoY to 17.1%. In H1, margins were hurt by 140bp due to ITC non-availability -50bp before and 90bp after September 22. Management clarified ceteris paribus impact on margins shall be 450bp. For H1, EV rose 10.4% YoY to INR253.6bn, driven by unwind (INR9bn), VNB (INR5.1bn), economic variance (INR2.3bn), partly offset by operating variance (INRO.9bn) including GST impact (INR1.05bn). Q2 PAT fell 91.2% YoY to INR130mn. Renewal premium growth of 30.3% YoY lifted AUM to INR1.3tn (+7.2% YoY).

Financials

Year to March (INR mn)	Q2FY26	Q2FY25	% Change	Q1FY26	% Change
Net Revenue	14,725	12,171	21.0	4,344	239.0
EBITDA	13,958	11,566	20.7	3,705	276.7
Adjusted Profit	10,852	9,076	19.6	3,299	228.9
Diluted EPS (INR)	6.8	5.7	19.6	2.1	228.9

Madhukar Ladha madhukar.ladha@nuvama.com Mahrukh Adaiania Mahrukh.Adajania@nuvama.com

Vaibhav Sharma VaibhavR.Sharma@nuvama.com

Nuvama Institutional Equities

Financial Statements

Income Statement (INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
Total operating income	22,617	26,009	29,911	34,397
Gross profit	0	0	0	0
Employee costs	1,581	1,818	2,091	2,404
Other expenses	875	918	964	1,012
EBITDA	20,162	23,273	26,856	30,981
Depreciation	43	41	43	45
Less: Interest expense	0	0	0	0
Add: Other income	375	431	496	570
Profit before tax	20,494	23,664	27,309	31,506
Prov for tax	4,905	5,959	6,877	7,933
Less: Other adj	0	0	0	0
Reported profit	15,589	17,705	20,433	23,573
Less: Excp.item (net)	0	0	0	0
Adjusted profit	15,589	17,705	20,433	23,573
Diluted shares o/s	1,600	1,600	1,600	1,600
Adjusted diluted EPS	9.7	11.1	12.8	14.7
DPS (INR)	1.0	1.7	1.9	2.2
Tax rate (%)	23.9	25.2	25.2	25.2

Balance Sheet (INR mn)

zalance sheet (nat mil)					
Year to March	FY25A	FY26E	FY27E	FY28E	
Share capital	1,596	1,596	1,596	1,596	
Reserves	82,123	97,172	114,540	134,578	
Shareholders funds	83,719	98,768	116,136	136,174	
Minority interest	0	0	0	0	
Borrowings	0	0	0	0	
Trade payables	85	87	89	91	
Other liabs & prov	1,295	1,440	1,606	1,793	
Total liabilities	85,248	100,439	117,991	138,237	
Net block	1,219	1,280	1,344	1,411	
Intangible assets	0	0	0	0	
Capital WIP	46	47	48	49	
Total fixed assets	1,265	1,327	1,392	1,460	
Non current inv	57,487	60,362	63,380	66,549	
Cash/cash equivalent	189	11,637	25,197	41,194	
Sundry debtors	12	13	14	16	
Loans & advances	518	570	627	690	
Other assets	22,007	23,137	24,327	25,580	
Total assets	85,248	100,439	117,991	138,237	

Important Ratios (%)

F				
Year to March	FY25A	FY26E	FY27E	FY28E
EBITDA margin (%)	89.1	89.5	89.8	90.1
Net profit margin (%)	68.9	68.1	68.3	68.5
Revenue growth (% YoY)	33.1	15.0	15.0	15.0
EBITDA growth (% YoY)	33.9	15.4	15.4	15.4
Adj. profit growth (%)	33.2	13.6	15.4	15.4

Free Cash Flow (INR mn)

	,			
Year to March	FY25A	FY26E	FY27E	FY28E
Reported profit	20,494	23,664	27,309	31,506
Add: Depreciation	43	41	43	45
Interest (net of tax)	0	0	0	0
Others	1,039	0	0	0
Less: Changes in WC	113	405	398	377
Operating cash flow	17,238	18,151	20,874	23,995
Less: Capex	(3,876)	(102)	(108)	(113)
Free cash flow	13,362	18,049	20,766	23,882

Assumptions (%)

Year to March	FY25A	FY26E	FY27E	FY28E
GDP (YoY %)	6.4	6.4	6.4	6.4
Repo rate (%)	6.5	6.5	6.5	6.5
USD/INR (average)	81.0	81.0	81.0	81.0

Key Ratios

Year to March	FY25A	FY26E	FY27E	FY28E
RoE (%)	20.9	19.4	19.0	18.7
RoCE (%)	27.4	25.9	25.4	25.0
Inventory days	nm	nm	nm	nm
Receivable days	0	0	0	0
Payable days	1	1	1	1
Working cap (% sales)	0	0	0	0
Gross debt/equity (x)	0	0	0	0
Net debt/equity (x)	(25.8)	(34.5)	(42.0)	(48.4)
Interest coverage (x)	0	0	0	0

Valuation Metrics

Year to March	FY25A	FY26E	FY27E	FY28E
Diluted P/E (x)	237.1	207.8	180.1	156.1
Price/BV (x)	44.0	37.3	31.7	27.0
EV/EBITDA (x)	156.8	135.3	116.7	100.6
Dividend yield (%)	0	0	0	0

Source: Company and Nuvama estimates

Valuation Drivers

Year to March	FY25A	FY26E	FY27E	FY28E
EPS growth (%)	32.9	14.1	15.4	15.4
RoE (%)	20.9	19.4	19.0	18.7
EBITDA growth (%)	33.9	15.4	15.4	15.4
Payout ratio (%)	10.2	15.0	15.0	15.0

Exhibit 1: SotP valuation based on Sep-27E earnings

	Parameter	Sep-27E	Multiple (x / %)	Stake (%)	Valuation (INR bn)	Bajaj Finserv's stake (INR bn)	Value/share (INR)	Share in SOTP	Comments
Bajaj Finance	CMP (INR)	950	1.0	51.5	5,89	3,036	1,897	83.7	CMP
Bajaj General Insurance	PAT	22.6	24.0	74.0	54:	1 401	200	8.8	18% discount to price multiple of ICICIGI
Bajaj Life insurance	EV	307.1	1.5	74.0	46:	1 341	170	7.5	45% discount to EV multiple of HDFCLIFE
Total					6,89	3,777	2,268	100	

Source: Company, Nuvama Research

Bajaj Allianz General Insurance Company (BAGIC)

Exhibit 2: NEP declines 9.6% YoY to INR24.1bn

(INR mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
GWP	58,710	66,260	43,260	52,020	64,130	9.2	23.3
NWP	27,096	24,738	20,171	23,390	25,425	(6.2)	8.7
NEP	26,600	24,030	22,700	22,290	24,040	(9.6)	7.9
Claims incurred	21,200	18,671	14,278	15,848	18,222	(14.0)	15.0
Commissions and expenses	5,880	5,789	8,452	7,602	6,738	14.6	(11.4)
Underwriting profits	-480	-430	-30	-1,160	-920	NM	NM
Investment Income	7,080	5,770	4,850	10,030	7,880	11.3	(21.4)
PBT	6,600	5,340	4,820	8,870	6,960	5.5	(21.5)
Tax	1,660	1,340	1,190	2,270	1,790	7.8	(21.1)
PAT	4,940	4,000	3,630	6,600	5,170	4.7	(21.7)

Source: Company, Nuvama Research

Exhibit 3: Combined ratio increases 90bp YoY to 102.3% while decreasing 130bp QoQ

Ratios (%)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Claims	79.7	77.7	62.9	71.1	75.8	(390)bp	470bp
Commission and opex	21.7	23.4	41.9	32.5	26.5	480bp	(600)bp
Combined	101.4	101.1	104.8	103.6	102.3	90bp	(130)bp
Retention rate (%)	46.2	37.3	46.6	45.0	39.6	(651)bp	(532)bp
Tax rate (%)	25.2	25.1	24.7	25.6	25.7	<i>57bp</i>	13bp

Exhibit 4: Share of motor increases 200bp YoY to 27% in GWP mix

Product mix - GWP basis (%)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Motor	25.0	25.0	41.0	33.0	27.0	200bp	(600)bp
Health (retail)	5.0	4.0	8.0	5.0	5.0	-	-
Health (group)	21.0	9.0	12.0	18.0	21.0	-	300bp
Property, liability, engineering	12.0	12.0	17.0	33.0	13.0	100bp	(2,000)bp
Agri	16.0	9.0	12.0	2.0	15.0	(100)bp	1,300bp
Health (government)	14.0	36.0	-	-	13.0	(100)bp	1,300bp
Others	7.0	5.0	10.0	9.0	6.0	(100)bp	(300)bp
Total	100	100	100	100	100		
Segments GWP (INR mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Motor	14,678	16,565	17,737	17,167	17,315	18.0	0.9
Health (retail)	2,936	2,650	3,461	2,601	3,207	9.2	23.3
Health (group)	12,329	5,963	5,191	9,364	13,467	9.2	43.8
Property, liability, engineering	7,045	7,951	7,354	17,167	8,337	18.3	(51.4)
Agri	9,394	5,963	5,191	1,040	9,620	2.4	824.6
Health (government)	8,219	23,854	0	0	8,337	1.4	NM
Others	4,110	3,313	4,326	4,682	3,848	(6.4)	(17.8)
Total	58,710	66,260	43,260	52,020	64,130	9.2	23.3

Source: Company, Nuvama Research

Exhibit 5: Motor loss ratio improves 110bp YoY driven by 720bp improvement in motor TP

Segment wise claims ratio (%)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Fire	77.6	19.1	-1.0	73.1	47.5	(3,010)bp	(2,560)bp
Marine Cargo	108.9	57.3	62.2	63.6	109.6	70bp	4,600bp
Motor OD	65.0	65.5	63.1	74.9	70.9	590bp	(400)bp
Motor TP	72.2	84.5	51.7	52.6	65.0	(720)bp	1,240bp
Motor	68.8	75.2	57.3	63.3	67.7	(110)bp	440bp
Engineering	38.0	24.6	-5.2	78.6	68.8	3,080bp	(980)bp
PA	39.3	58.8	73.0	NA*	NA*	(3,930)bp	-
Health	95.5	91.6	84.3	82.8*	89.8	(570)bp	700bp
Crop	93.8	97.9	17.2	49.7	74.5	(1,930)bp	2,480bp
Total	79.7	77.7	62.9	71.1	75.8	(390)bp	470bp

Source: Company, Nuvama Research

Note: * For Q1FY26 and Q2FY26, company reported combined loss ratio of PA, Health and Travel

Exhibit 6: Share of brokers increases 300bp YoY to 35.0% in channel mix, direct channel remains flat at 40.0%

Channel mix - GWP basis (%)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Brokers	32.0	33.0	67.0	55.0	35.0	300bp	(2,000)bp
Direct	40.0	50.0	2.0	15.0	40.0	-	2,500bp
Individual	12.0	10.0	19.0	15.0	12.0	-	(300)bp
Corporate agents- Others	2.0	1.0	2.0	2.0	1.0	(100)bp	(100)bp
Corporate Banks- Others	10.0	6.0	10.0	8.0	7.0	(300)bp	(100)bp
Others*	4.0	-	-	5.0	5.0	100bp	-
Total	100	100	100	100	100		
Channel mix - GWP basis (INR mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Brokers	18,787	21,866	28,984	28,611	22,446	19.5	(21.5)
Direct	23,484	33,130	865	7,803	25,652	9.2	228.7
Individual	7,045	6,626	8,219	7,803	7,696	9.2	(1.4)
Corporate agents- Others	1,174	663	865	1,040	641	(45.4)	(38.4)
Corporate Banks- Others	5,871	3,976	4,326	4,162	4,489	(23.5)	7.9
Others*	2,348	-	-	2,601	3,207	36.5	23.3
Total	58,710	66,260	43,260	52,020	64,130		

Source: Company, Nuvama Research

Note: * Others include Customer service centres, IMF, POSP, MISP & Web aggregators

Exhibit 7: Investment yield improves 8bp YoY to 9%


	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY (%)	QoQ(%)
Investment book (INR bn)	319.5	326.3	331.2	352.0	349.7	9.5	(0.6)
Investment yield (%)	8.9	7.1	5.9	11.7	9.0	8bp	(276)bp

Source: Company, Nuvama Research

Exhibit 8: BAGIC estimate change


		Earlier			Revised		C	Change (%/bp)	
INR mn	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net written premium	122,820	143,178	164,688	122,820	143,178	164,688	-	-	-
Net earned premium	112,994	131,581	151,348	112,994	131,581	151,348	-	-	-
COR (%) IRDAI	101.6	101.5	100.8	101.6	101.5	100.8	0bp	0bp	0bp
Underwriting profits	(4,638)	(5,221)	(4,879)	(4,638)	(5,221)	(4,879)	-	-	-
Investment book	394,486	458,477	526,326	394,486	458,477	526,326	-	-	-
APAT	19,868	22,557	25,948	19,868	22,557	25,948	-	-	-
EPS	180.2	204.6	235.4	180.2	204.6	235.4	-	-	-
ROE (%)	15.5	15.6	15.8	15.5	15.6	15.8	0bp	0bp	0bp

Exhibit 9: NEP declines 9.6% YoY




Source: Company, Nuvama Research

Exhibit 11: Share of motor improves 200bp YoY




Source: Company, Nuvama Research

Exhibit 10: COR decreases 90bp YoY to 102.3%



Source: Company, Nuvama Research

Exhibit 12: RPAT improves 4.7% YoY to INR 5.2bn



Source: Company, Nuvama Research

Bajaj Allianz Life Insurance Company (BALIC)

Exhibit 13: Total APE declines 5.2% YoY, VNB margin improves 628bp YoY to 17.1%

(INR mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY(%)	QoQ(%)
Total APE	22,680	16,850	24,860	13,100	21,490	(5.2)	64.0
Individual APE	18,950	15,490	23,280	12,550	18,500	(2.4)	47.4
Group APE	3,730	1,360	1,580	550	2,990	(19.8)	443.6
Renewal premium	33,420	36,000	54,480	31,620	43,540	30.3	37.7
Gross written premium	65,440	63,610	92,370	54,780	83,660	27.8	52.7
VNB	2,450	2,540	5,490	1,450	3,670	49.8	153.1
VNB Margin (%)	10.8	15.1	22.1	11.1	17.1	628bp	601bp
PAT	1,480	2,220	410	1,710	130	(91.2)	(92.4)

Source: Nuvama Research, Company

Exhibit 14: Protection business clocks growth of 400bp YoY

Individual APE mix (%)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY(%)	QoQ(%)
ULIP	51.0	44.0	40.0	45.0	45.0	(600)bp	-
PAR	24.0	27.0	21.0	22.0	21.0	(300)bp	(100)bp
Non-PAR	17.0	17.0	27.0	19.0	19.0	200bp	-
Protection	4.0	7.0	6.0	9.0	8.0	400bp	(100)bp
Annuity	4.0	5.0	6.0	5.0	7.0	300bp	200bp
Total	100	100	100	100	100		
Group NBP mix							
Savings	45.7	44.9	51.1	23.9	62.1	1,647bp	3,823bp
Protection	54.3	55.1	48.9	76.1	37.9	(1,647)bp	(3,823)bp
Total	100	100	100	100	100		
Individual APE mix (INR mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY(%)	QoQ(%)
ULIP	9,665	6,816	9,312	5,648	8,325	(13.9)	47.4
PAR	4,548	4,182	4,889	2,761	3,885	(14.6)	40.7
Non-PAR	3,222	2,633	6,286	2,385	3,515	9.1	47.4
Protection	758	1,084	1,397	1,130	1,480	95.3	31.0
Total	18,950	15,490	23,280	12,550	18,500	(2.4)	47.4
Group NBP mix							
Savings	5,120	4,960	6,770	2,200	12,310	140.4	459.5
Protection	6,090	6,090	6,480	7,000	7,500	23.2	7.1
Total	11,210	11,050	13,250	9,200	19,810	76.7	115.3

Source: Company, Nuvama Research

Exhibit 15: Agency channel declines 15.2% YoY, institutional channel grows 7.2% YoY

Distribution mix - Ind mix (INR mn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY(%)	QoQ(%)
Agency	7,520	5,480	7,050	4,680	6,380	(15.2)	36.3
Institutional	9,000	7,880	13,290	6,120	9,650	7.2	57.7
Others	2,420	2,130	2,940	1,750	2,470	2.1	41.1
Total	18,940	15,490	23,280	12,550	18,500	(2.3)	47.4
Distribution mix - Ind mix (%)							
Agency	39.7	35.4	30.3	37.3	34.5	(522)bp	(280)bp
Institutional	47.5	50.9	57.1	48.8	52.2	464bp	340bp
Others	12.8	13.8	12.6	13.9	13.4	57bp	(59)bp
Total	100	100	100	100	100		

Source: Company, Nuvama Research

Exhibit 16: Share of linked AUM declines 195bp YoY to 39.2%

AUM (INR bn)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY(%)	QoQ(%)
Linked	506.3	481.5	472.6	519.1	517.1	2.1	(0.4)
Non-linked	725.4	738.7	764.7	791.4	803.5	10.8	1.5
Total	1,231.8	1,220.2	1,237.4	1,310.5	1,320.6	7.2	0.8
AUM mix (%)							
Linked	41.1	39.5	38.2	39.6	39.2	(195)bp	(45)bp
Non-linked	58.9	60.5	61.8	60.4	60.8	195bp	45bp
Total	100	100	100	100	100		

Exhibit 17: Persistency deteriorates except 25th and 61st months YoY

Persistency (%)	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	YoY(%)	QoQ(%)
13th month	85	84	83	82	82	-310bps	0bps
25th month	73	73	74	75	75	210bps	0bps
37th month	65	65	64	64	65	-10bps	100bps
49th month	64	62	61	61	63	-70bps	200bps
61st month	52	52	52	52	55	310bps	300bps

Source: Company, Nuvama Research

Exhibit 18: BALIC Estimate change

		Earlier			Revised			Change (%/bp)	
INR bn	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
APE	85.1	97.3	110.3	86.3	98.8	112.0	1.4	1.5	1.6
VNB	12.9	15.0	17.4	12.8	16.7	19.4	(0.9)	11.1	11.2
VNB Margin (%)	15.2	15.5	15.8	14.8	16.9	17.3	-35bp	146bp	149bp
Embedded Value	266.1	303.0	345.3	268.4	307.1	351.7	0.8	1.4	1.9
Operating RoEV (%)	13.3	13.9	14.0	13.0	14.4	14.5	-26bp	58bp	56bp


Source: Company, Nuvama Research

Exhibit 19: Total APE shrinks 5.2% YoY



Source: Company, Nuvama Research

Exhibit 21: ULIP share in APE mix declines YoY




Source: Company, Nuvama Research

Exhibit 20: VNB margin surges 628bp YoY to 17.1% YoY



Source: Company, Nuvama Research

Exhibit 22: Institutional channel share improves 464bp YoY



Q2FY26 earnings call: Key highlights

Separate listing of life and general insurance companies: Listing of life and general insurers unlikely in next two–three years; focus remains on completing Allianz acquisition in coming months. Review to follow post implementation of Insurance Act, RBC, and IND AS.

Allianz exit - CCI and IRDAI have approved the acquisition of Allianz's stake, expected to be completed in the coming months. Management sees this as an opportunity to leverage the Bajaj brand and scale up its insurance businesses.

BAGIC

GWP:

The company aims to maintain market share across all business lines. TP market share has fallen below OD, and efforts are underway to improve it. Retail health growth was muted due to the impact of long-term policies (e.g., 1-year to multi-year shift). Excluding 1/n impact, growth in Q2 was 11% YoY and growth stood is at 15% YoY in October.

Claim ratio and profitability: Management noted that in two-wheelers, market share rose from 3% three years ago to ~13.5–14% in Q2 and upfront commission payments for 5-year policies pressurises profitability. Also, in four-wheelers, market share increased from 7.5% to 9% and the long-term nature of the business weighs on margins. Management said that Motor OD loss ratio stood at 70.9% in Q2FY26 and is expected to improve for the full year.

The company retains flexibility to offset the impact of ITC non-availability in retail health through other business segments.

Business segments: Management highlighted that BAGIC had outperformed industry growth in motor, retail health, and commercial segments. It stated that group health continues to witness pricing pressure and remains a tactical play. It stated that BAGIC had stopped pursuing the crop segment aggressively as competitive intensity had increased and pricing was not appropriate.

Underwriting loss: Underwriting losses remain elevated, driven by higher acquisition costs. The company is focusing on writing preferred and profitable business lines to improve underwriting performance.

Combined ratio: Management highlighted that the combined ratio stood at 102.3% in Q2FY26, well below the industry average of 115–120%, outperforming peers by 15–20%. The shift to long-term (1/n) policies added ~1% to the ratio, and efforts are underway to bring it below 100%.

BALIC

APE: APE growth slowed recently as the company undertook a strategic overhaul of its product portfolio. Management expects topline growth to resume from H2FY26 onwards. The focus remains on driving VNB growth, which is likely to outpace APE growth in FY26. Further tailwinds from the GST exemption are likely to support growth momentum.

VNB margin: Management attributed the improvement in VNB margin to a structurally stronger cost framework, driven by cost optimisation (100—150bp), product mix shift (~400bp), and product repricing. Margins have also benefited from riders, operational efficiency, and operating leverage gains. The overall margin expansion journey remains on track. Management expects significant improvement ahead, with GST impact likely to fade over the next two quarters. Without the GST effect, margins would have expanded by 4–6%.

GST impact: Loss of ITC has weighed on profitability, though the full benefit of GST exemption will be passed on to customers. Management expects to offset the ITC loss over the next two–three quarters.

In H1, margins were hurt by ~140bp due to GST-50bp before and 90bp after the September 22. Post-exemption sales were skewed toward non-ULIP products. If unaddressed, the annualised impact of ITC non-availability would be ~450bp. However, the company has already taken mitigating actions, including product restructuring, mix optimisation and renegotiation with distributors and vendors to share the cost burden. Management expects the full impact to normalise within two quarters.

Product mix: Management see continued growth potential in the protection segment. Currently, 43% of new customers are term buyers, and an additional 17% have opted for riders. High–sum assured ULIPs account for ~8–10% of the overall mix.

Retail protection has shown steady growth over the past 18–24 months, and management expects its share to reach ~10% over the next two–three years. The company plans to maintain its current overall product mix in the medium term.

Company Description

Bajaj Finserv Limited (BJFIN) is the holding company of the financial services business of Sanjiv Bajaj's Bajaj group, which houses three key businesses: i) lending through Bajaj Finance (BFL); ii) general insurance under Bajaj Allianz General Insurance Company (BAGIC); and iii) life insurance under Bajaj Allianz Life Insurance Company (BALIC).

Bajaj Direct – marketplace for financial products, Bajaj Health – a health ecosystem enabler, and Bajaj Asset management – asset management – are three emerging businesses under the company. Additionally, BJFIN operates wind farm assets in Maharashtra. The company is a Core Investment Company (CIC) under the regulations of the Reserve Bank of India (RBI).

Key Subsidiaries:

- **1. Bajaj Finance Limited (BFL):** Bajaj Finance Limited (BFL) is a leading retail-focused NBFC with a well-diversified product mix across consumer lending, personal loans, mortgages, commercial lending, LAS and SME lending. BFL has an AUM of INR 4.16 tn (as on Mar-25). Since inception, the company has leveraged technology to launch 22 product lines and 57 product variants across channels.
- **2. Bajaj Allianz General Insurance Company (BAGIC):** BAGIC is a leading private multi-line general insurer offering key products in the motor, health, crop and commercial segments. BAGIC has a vast product portfolio, key retail focus and strong multi-line distribution mix. BAGIC's NEP increased at an FY20–25 CAGR of 3.1% and commands a market share of 7.0% in FY25. It generated a profit after tax of INR 18.3bn in FY25 with a solvency level of 325%.
- **3. Bajaj Allianz Life Insurance Company (BALIC):** BALIC is a leading private life insurer having diversified product and channel mix. BALIC clocked a strong APE CAGR of 28.2% over FY20–25, commanding a individual APE market share of 8.3% among private players and 5.9% in the industry in FY25. The company generated net VNB of INR11.5bn at a margin of 14.6%.

Key risks

Key risks include any sharp growth slowdown, increased competitive intensity as a large strong player is expected to enter financial services; any strong hit to underwriting profitability, change in regulations by RBI or IRDAI

Additional Data

Management

Chairman & MD	Sanjeev Bajaj
CFO	Ramandeep Singh
MD & CEO - BAGIC	Tapan Singhel
MD & CEO - BALIC	Tarun Chugh
Auditor	KKC & Associates LLP

Recent Company Research

Date	Title	Price	Reco
25-Jul-25	Profitability in focus; Result Update	2,032	Hold
30-Apr-25	Margin focus to drive earnings; Result Update	1,952	Hold
31-Jan-25	Focusing on profitability; Result Update	1,672	Hold

Holdings – Top 10*


	% Holding		% Holding
Jaya Hind Indus	3.93	Bacchraj & Co.	1.46
SBI Funds Manag	2.57	ICICI Prudentia	1.40
Maharashtra Sco	2.37	Bajaj Niraj	1.33
LIC	1.84	Vanguard Group	1.03
Bajaj Sevashram	1.67	Blackrock	0.89

^{*}Latest public data

Recent Sector Research

Date	Name of Co./Sector	Title		
11-Nov-25	Other financial services	Oct-25: Strong SIP flows sustain; Sector Update		
05-Nov-25	MEDI ASSIST HEALTHCARE SERVICES	Low growth; integration hurts margins; Result Update		
01-Nov-25	CDSL (India)	Revenue growth-driven earnings beat; Result Update		

Rating and Daily Volume Interpretation



Source: Bloomberg, Nuvama research

Rating Rationale & Distribution: Nuvama Research

Rating	Expected absolute returns over 12 months	Rating Distribution
Buy	15%	205
Hold	<15% and >-5%	68
Reduce	<-5%	37

DISCLAIMER

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801- 804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance officer: Mr. Abhijit Talekar, E-mail address: researchcompliance@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address - grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address - grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address - grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address - grievance.nwm@nuvama.com Contact details +91 9004510449 Investor Grievance e-mail address - g

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future p

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients other than intended recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company in the last 12 month period ending on the last day of the month immediately preceding the date of publication of the Report.: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Artificial Intelligence ("AI") tools may have been used (i) during the information gathering stage for compiling or collating the data from-(a) publicly available data sources; (b) databases to which NWML subscribes; and (c) internally generated research data, and/or (ii) for compiling summaries of the report.

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 273 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING. REGISTRATION GRANTED BY SEBI, MEMBERSHIP OF RAASB AND CERTIFICATION FROM NISM IN NO WAY GUARANTEE PERFORMANCE OF NWML OR PROVIDE ANY ASSURANCE OF RETURNS TO INVESTORS AND CLIENTS.

Abneesh Roy Head of Research Committee Abneesh.Roy@nuvama.com